Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luveltamab tazevibulin in infants and children under 12 with relapsed or refractory CBFA2T3::GLIS2-positive AML
NL-OMON59519Phase 2Completed
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luveltamab tazevibulin in acute myeloid leukemia (AML), sponsored by Sutro Biopharma, Inc. Primary endpoint: Complete remission rate. Started Sep 2024; status: completed.
02
Drugs
luveltamab tazevibulin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON59519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59519.